Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURESTEM-AD for Moderate to Severe Chronic Atopic Dermatitis
NCT05004324Phase 3Unknown
- Sponsor
- Kangstem Biotech
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Furestem-AD Inj. Group with Placebo Group (2 arms). Primary endpoint: Eczema Area and Severity Index-50 at 12 weeks. Status: unknown.
02
Drugs
Promostem
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05004324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004324.